FHA
DNA icon

First Horizon Advisors’s Ginkgo Bioworks DNA Stock Holding History

First Horizon Advisors’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-760
Closed -$10.2K – 2337
2024
Q2 		$10.2K Sell
760
-56
-7% -$1.67K ﹤0.01% 1527
2024
Q1 		$37.9K Buy
816
+127
+18% +$6.57K ﹤0.01% 1086
2023
Q4 		$46.6K Buy
689
+80
+13% +$4.9K ﹤0.01% 969
2023
Q3 		$44.1K Sell
609
-189
-24% -$15.1K ﹤0.01% 906
2023
Q2 		$59.4K Buy
798
+116
+17% +$6.87K ﹤0.01% 816
2023
Q1 		$36.3K Buy
682
+168
+33% +$10.6K ﹤0.01% 1040
2022
Q4 		$34.8K Buy
514
+35
+7% +$3.22K ﹤0.01% 1013
2022
Q3 		$59K Buy
479
+72
+18% +$8.58K ﹤0.01% 779
2022
Q2 		$38K Buy
+407
New +$49.6K ﹤0.01% 1032

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

First Horizon Advisors's DNA Position: Q3 2024 in Review

First Horizon Advisors sold out of Ginkgo Bioworks (DNA) in Q3 2024, closing a stake of 760 shares — an estimated $10.2K sold.

First Horizon Advisors first reported a position in DNA in Q2 2022 and held it in 9 quarters. The position peaked at $59.4K in Q2 2023. 159 funds tracked by Wall St. Rank hold DNA as of Q3 2024.

  • First Horizon Advisors reported no remaining Ginkgo Bioworks position as of Q3 2024 after selling out during the quarter.
  • First Horizon Advisors sold 760 Ginkgo Bioworks shares in Q3 2024, an estimated $10.2K.
  • First Horizon Advisors first reported a position in Ginkgo Bioworks in Q2 2022 and held it in 9 quarters.
  • First Horizon Advisors's Ginkgo Bioworks position peaked at $59.4K in Q2 2023.
  • 159 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2024.

Based on First Horizon Advisors's 13F filing for Q3 2024, filed 8 Nov 2024.